JP2021516046A - 新規アデノ随伴ウイルス(aav)ベクター、低減されたカプシド脱アミド化を有するaavベクター、およびその使用 - Google Patents

新規アデノ随伴ウイルス(aav)ベクター、低減されたカプシド脱アミド化を有するaavベクター、およびその使用 Download PDF

Info

Publication number
JP2021516046A
JP2021516046A JP2020545160A JP2020545160A JP2021516046A JP 2021516046 A JP2021516046 A JP 2021516046A JP 2020545160 A JP2020545160 A JP 2020545160A JP 2020545160 A JP2020545160 A JP 2020545160A JP 2021516046 A JP2021516046 A JP 2021516046A
Authority
JP
Japan
Prior art keywords
hsa
mir
capsid
seq
aav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020545160A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021516046A5 (cg-RX-API-DMAC7.html
Inventor
ウイルソン,ジェームス・エム
テペ,エイプリル
ターナー,ケビン
シムス,ジョシュア・ジョイナー
Original Assignee
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア filed Critical ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア
Publication of JP2021516046A publication Critical patent/JP2021516046A/ja
Publication of JP2021516046A5 publication Critical patent/JP2021516046A5/ja
Priority to JP2023131761A priority Critical patent/JP2023159235A/ja
Priority to JP2024005924A priority patent/JP2024041967A/ja
Priority to JP2025188265A priority patent/JP2026027394A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2020545160A 2018-02-27 2019-02-27 新規アデノ随伴ウイルス(aav)ベクター、低減されたカプシド脱アミド化を有するaavベクター、およびその使用 Pending JP2021516046A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2023131761A JP2023159235A (ja) 2018-02-27 2023-08-14 新規アデノ随伴ウイルス(aav)ベクター、低減されたカプシド脱アミド化を有するaavベクター、およびその使用
JP2024005924A JP2024041967A (ja) 2018-02-27 2024-01-18 新規アデノ随伴ウイルス(aav)ベクター、低減されたカプシド脱アミド化を有するaavベクター、およびその使用
JP2025188265A JP2026027394A (ja) 2018-02-27 2025-11-07 新規アデノ随伴ウイルス(aav)ベクター、低減されたカプシド脱アミド化を有するaavベクター、およびその使用

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862635964P 2018-02-27 2018-02-27
US62/635,964 2018-02-27
US201862677471P 2018-05-29 2018-05-29
US201862667585P 2018-05-29 2018-05-29
US62/667,585 2018-05-29
US62/677,471 2018-05-29
US201862703670P 2018-07-26 2018-07-26
US62/703,670 2018-07-26
US201862722382P 2018-08-24 2018-08-24
US62/722,382 2018-08-24
PCT/US2019/019804 WO2019168961A1 (en) 2018-02-27 2019-02-27 Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2023131761A Division JP2023159235A (ja) 2018-02-27 2023-08-14 新規アデノ随伴ウイルス(aav)ベクター、低減されたカプシド脱アミド化を有するaavベクター、およびその使用
JP2024005924A Division JP2024041967A (ja) 2018-02-27 2024-01-18 新規アデノ随伴ウイルス(aav)ベクター、低減されたカプシド脱アミド化を有するaavベクター、およびその使用

Publications (2)

Publication Number Publication Date
JP2021516046A true JP2021516046A (ja) 2021-07-01
JP2021516046A5 JP2021516046A5 (cg-RX-API-DMAC7.html) 2022-02-18

Family

ID=67805569

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020545160A Pending JP2021516046A (ja) 2018-02-27 2019-02-27 新規アデノ随伴ウイルス(aav)ベクター、低減されたカプシド脱アミド化を有するaavベクター、およびその使用
JP2023131761A Pending JP2023159235A (ja) 2018-02-27 2023-08-14 新規アデノ随伴ウイルス(aav)ベクター、低減されたカプシド脱アミド化を有するaavベクター、およびその使用
JP2024005924A Pending JP2024041967A (ja) 2018-02-27 2024-01-18 新規アデノ随伴ウイルス(aav)ベクター、低減されたカプシド脱アミド化を有するaavベクター、およびその使用
JP2025188265A Pending JP2026027394A (ja) 2018-02-27 2025-11-07 新規アデノ随伴ウイルス(aav)ベクター、低減されたカプシド脱アミド化を有するaavベクター、およびその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2023131761A Pending JP2023159235A (ja) 2018-02-27 2023-08-14 新規アデノ随伴ウイルス(aav)ベクター、低減されたカプシド脱アミド化を有するaavベクター、およびその使用
JP2024005924A Pending JP2024041967A (ja) 2018-02-27 2024-01-18 新規アデノ随伴ウイルス(aav)ベクター、低減されたカプシド脱アミド化を有するaavベクター、およびその使用
JP2025188265A Pending JP2026027394A (ja) 2018-02-27 2025-11-07 新規アデノ随伴ウイルス(aav)ベクター、低減されたカプシド脱アミド化を有するaavベクター、およびその使用

Country Status (13)

Country Link
US (1) US20200407750A1 (cg-RX-API-DMAC7.html)
EP (1) EP3758724A4 (cg-RX-API-DMAC7.html)
JP (4) JP2021516046A (cg-RX-API-DMAC7.html)
KR (1) KR20210010434A (cg-RX-API-DMAC7.html)
CN (2) CN119842635A (cg-RX-API-DMAC7.html)
AU (1) AU2019227726B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020017348A2 (cg-RX-API-DMAC7.html)
CA (1) CA3091806A1 (cg-RX-API-DMAC7.html)
CL (2) CL2020002200A1 (cg-RX-API-DMAC7.html)
IL (1) IL276859B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020008933A (cg-RX-API-DMAC7.html)
SG (1) SG11202008182TA (cg-RX-API-DMAC7.html)
WO (1) WO2019168961A1 (cg-RX-API-DMAC7.html)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL314171A (en) 2015-09-28 2024-09-01 Univ Florida Methods and compositions for antibody-evading virus vectors
MX2020010465A (es) 2018-04-03 2021-01-08 Vectores de virus para direccionamiento a tejidos oftalmicos.
CA3095179A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Antibody-evading virus vectors
BR112020020266A2 (pt) 2018-04-03 2021-01-19 Stridebio, Inc. Vetores de vírus com evasão de anticorpos
AU2019354296A1 (en) 2018-10-01 2021-04-29 Ultragenyx Pharmaceutical Inc. Gene therapy for treating propionic acidemia
CN113727992A (zh) 2019-03-21 2021-11-30 斯特里迪比奥公司 重组腺相关病毒载体
WO2020223232A1 (en) 2019-04-29 2020-11-05 The Trustees Of The University Of Pennsylvania Novel aav capsids and compositions containing same
WO2021067598A1 (en) 2019-10-04 2021-04-08 Ultragenyx Pharmaceutical Inc. Methods for improved therapeutic use of recombinant aav
MX2022004353A (es) 2019-10-17 2022-07-19 Casete de transferencia de aav.
CN114787180A (zh) 2019-10-17 2022-07-22 斯特里迪比奥公司 用于治疗c型尼曼-匹克病的腺相关病毒载体
AU2020369508A1 (en) * 2019-10-21 2022-05-26 The Trustees Of The University Of Pennsylvania AAV3B variants with improved production yield and liver tropism
EP4085255A1 (en) 2020-01-03 2022-11-09 Sarepta Therapeutics, Inc. Methods for analyzing aav capsid proteins
AU2021218703A1 (en) * 2020-02-14 2022-07-28 Ultragenyx Pharmaceutical Inc. Gene therapy for treating CDKL5 deficiency disorder
US12686874B2 (en) 2020-03-31 2026-07-21 Ultragenyx Pharmaceutical Inc. Gene therapy for treating propionic acidemia
JP7862321B2 (ja) * 2020-04-27 2026-05-19 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Cdkl5欠損症(cdd)の治療において有用な組成物
CA3183153A1 (en) 2020-06-17 2021-12-23 Christian HINDERER Compositions and methods for treatment of gene therapy patients
WO2022015715A1 (en) 2020-07-13 2022-01-20 The Trustees Of The University Of Pennsylvania Compositions useful for treatment of charcot-marie-tooth disease
JP2023542614A (ja) 2020-08-19 2023-10-11 サレプタ セラピューティクス, インコーポレイテッド レット症候群の治療のためのアデノ随伴ウイルスベクター
WO2022082109A1 (en) * 2020-10-18 2022-04-21 The Trustees Of The University Of Pennsylvania Improved adeno-associated virus (aav) vector and uses therefor
MX2023005113A (es) * 2020-10-29 2023-08-04 Univ Pennsylvania Cápsides de aav y composiciones que las contienen.
AR124216A1 (es) 2020-12-01 2023-03-01 Univ Pennsylvania Composiciones nuevas con motivos selectivos específicos del tejido y composiciones que las contienen
MX2023008826A (es) 2021-02-01 2023-09-15 Regenxbio Inc Terapia génica para lipofuscinosis neuronal ceroidea.
IL307633A (en) 2021-04-12 2023-12-01 Univ Pennsylvania Useful preparations in the treatment of spinal muscular atrophy (SBMA)
AU2022262771A1 (en) 2021-04-23 2023-11-02 The Trustees Of The University Of Pennsylvania Novel compositions with brain-specific targeting motifs and compositions containing same
WO2023125481A1 (zh) * 2021-12-28 2023-07-06 成都弘基生物科技有限公司 经过修饰的aav衣壳蛋白及其用途
TW202340467A (zh) 2022-01-10 2023-10-16 賓州大學委員會 有用於治療c9orf72介導之病症之組成物及方法
US20250177495A1 (en) 2022-01-10 2025-06-05 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of metachromatic leukodystrophy
CN119317718A (zh) 2022-01-25 2025-01-14 宾夕法尼亚州大学信托人 用于改善心脏转导和肝脏去靶向的aav衣壳
CA3245327A1 (en) 2022-03-07 2023-09-14 Ultragenyx Pharmaceutical Inc. MODIFIED BATCH-BASED AAV PRODUCTION SYSTEMS AND PROCESSES
US20250250326A1 (en) 2022-04-06 2025-08-07 The Trustees Of The University Of Pennsylvania Passive immunization with anti-aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors
CN115011601B (zh) * 2022-06-27 2023-07-21 山东大学齐鲁医院 一种干扰JUND表达的shRNA、重组腺相关病毒载体及其应用
WO2024015966A2 (en) * 2022-07-15 2024-01-18 The Trustees Of The University Of Pennsylvania Recombinant aav having aav clade d and clade e capsids and compositions containing same
CN116350801A (zh) * 2022-11-22 2023-06-30 四川至善唯新生物科技有限公司 一种重组腺相关病毒载体的药物组合物及其用途
EP4634394A2 (en) 2022-12-17 2025-10-22 The Trustees of The University of Pennsylvania Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same
WO2024130070A2 (en) 2022-12-17 2024-06-20 The Trustees Of The University Of Pennsylvania Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof
JP2026502876A (ja) * 2022-12-23 2026-01-27 スパーク セラピューティクス インコーポレイテッド アデノ随伴ウイルス製剤
JP2026515815A (ja) * 2023-05-03 2026-05-19 ボイジャー セラピューティクス インコーポレイテッド Cdkl5欠損に関連する障害の治療のための組成物及び方法
IL324036A (en) * 2023-05-03 2025-12-01 Voyager Therapeutics Inc Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency
WO2025007046A1 (en) 2023-06-29 2025-01-02 The Trustees Of The University Of Pennsylvania Mutant aav with central nervous system targeting motifs and compositions containing same
WO2025102034A1 (en) 2023-11-10 2025-05-15 The Trustees Of The University Of Pennsylvania Gene therapy for barth syndrome
KR20260114566A (ko) 2023-11-14 2026-07-22 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 심근 및 골격근-특이적 표적화 모티프를 갖는 조성물 및 이의 용도
WO2026074494A1 (en) 2024-10-03 2026-04-09 Sarepta Therapeutics, Inc. Modified viral capsids and uses thereof
WO2026122921A1 (en) 2024-12-05 2026-06-11 The Trustees Of The University Of Pennsylvania Gene therapy for barth syndrome

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015514427A (ja) * 2012-04-18 2015-05-21 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia Aavカプシドバリアントを使用した高効率な遺伝子導入のための組成物及び方法
JP2016525356A (ja) * 2013-07-22 2016-08-25 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア 変異aav、及び、細胞、臓器並びに組織への遺伝子導入のための組成物、方法並びに使用法
WO2018035059A1 (en) * 2016-08-15 2018-02-22 Genzyme Corporation Methods for detecting aav

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1668143B1 (en) * 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
DE23193606T1 (de) * 2005-04-07 2024-02-15 The Trustees Of The University Of Pennsylvania Verfahren zur erhöhung der funktion eines aav-vektors
WO2017100674A1 (en) * 2015-12-11 2017-06-15 The Trustees Of The University Of Pennsylvania Scalable purification method for aav1
CN109661470A (zh) * 2016-04-15 2019-04-19 宾夕法尼亚州大学信托人 新型aav8突变衣壳和含有其的组合物
RS65241B1 (sr) * 2017-02-28 2024-03-29 Univ Pennsylvania Vektor adeno-asociranih virusa (aav) iz podgrupe f i njegove upotrebe

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015514427A (ja) * 2012-04-18 2015-05-21 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia Aavカプシドバリアントを使用した高効率な遺伝子導入のための組成物及び方法
JP2016525356A (ja) * 2013-07-22 2016-08-25 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア 変異aav、及び、細胞、臓器並びに組織への遺伝子導入のための組成物、方法並びに使用法
WO2018035059A1 (en) * 2016-08-15 2018-02-22 Genzyme Corporation Methods for detecting aav

Also Published As

Publication number Publication date
CL2022003757A1 (es) 2023-05-19
US20200407750A1 (en) 2020-12-31
JP2026027394A (ja) 2026-02-18
SG11202008182TA (en) 2020-09-29
KR20210010434A (ko) 2021-01-27
JP2024041967A (ja) 2024-03-27
AU2019227726A1 (en) 2020-09-10
WO2019168961A1 (en) 2019-09-06
CA3091806A1 (en) 2019-09-06
BR112020017348A2 (pt) 2020-12-29
IL276859B1 (en) 2025-08-01
CN112352050A (zh) 2021-02-09
EP3758724A1 (en) 2021-01-06
JP2023159235A (ja) 2023-10-31
EP3758724A4 (en) 2022-07-06
AU2019227726B2 (en) 2025-09-04
MX2020008933A (es) 2021-01-15
CN119842635A (zh) 2025-04-18
IL276859A (en) 2020-10-29
IL276859B2 (en) 2025-12-01
CL2020002200A1 (es) 2021-01-29

Similar Documents

Publication Publication Date Title
JP7860169B2 (ja) 新規アデノ随伴ウイルス(aav)ベクター、低減されたカプシド脱アミド化を有するaavベクター、およびその使用
AU2019227726B2 (en) Novel adeno-associated virus (AAV) vectors, aav vectors having reduced capsid deamidation and uses therefor
JP7754872B2 (ja) 新規アデノ随伴ウイルス(aav)クレードfベクター及びその用途
WO2022067228A1 (en) Trans-splicing system for tissue-specific replacement of rna sequences
HK40130495A (en) Novel adeno-associated virus (aav) vector, aav vector with reduced capsid deamidation, and use thereof
EA049701B1 (ru) Новые векторы на основе аденоассоциированного вируса (aav), векторы aav, со сниженным дезамидированием капсида, а также их применение
BR122025013279A2 (pt) Sistema de produção de raav adequado para a produção de um aavhu68 recombinante, cultura de células de produção, métodos para produzir um raavhu68 e para separar raavhu68 da cultura de células
EA048431B1 (ru) Вектор на основе аденоассоциированного вируса (aav) клады f и его применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230515

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230814

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230920